Company profile
VivoSim Labs, Inc.
NASDAQ: VIVS · Healthcare · Biotechnology
#1027 of 1,422 Healthcare companies by revenue72nd-percentile growth
EA Score
——FH —DQ —GM —SS 42
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, revenue growth (YoY) · ↓ operating margin, 3-yr revenue growth
Methodology →Revenue TTM
$131.0k
Rev growth YoY (TTM)
-9.0%
Net income (FY)
-$2.5M
Employees
15
as of 2026-08-24
Market cap
$734.6k
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$144.0k$144.0k2025
Net income-$2.5M-$2.5M2025
Operating income-$12.6M-$12.6M2025
Total assets$14.7M$14.7M2025
Liabilities$4.2M$4.2M2025
Equity$10.5M$10.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2026
By product
Royalty100%
By geography
Not disclosed.
The read
What is VivoSim Labs, Inc.’s revenue?
VivoSim Labs, Inc. booked $144.0k in FY2025 revenue, growing 32% year over year — faster than most Healthcare companies we track, at a -1727.8% net margin.
Peers · Healthcare
ZIVO Bioscience, Inc.——Cannabis Strategic Ventures——Anthera Pharmaceuticals, Inc.——Sigyn Therapeutics, Inc.——Endonovo Therapeutics, Inc.——Serina Therapeutics, Inc.41DNeighbors
San Diego →Key facts
CEOKeith Murphy
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: VIVS
Employees15
IPO date2012-02-14
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.